Please assess the completion status of the following clinical trial:

Trial Title: Use of Teriparatide to Accelerate Fracture Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be menopausal (no menses within the last 12 months)~* Low energy fragility fractures of the pelvis, including anterior column, posterior column, inferior or superior rami, or sacrum~* Maximum of 2 weeks post fracture~* Mental status consistent with completing the study protocol~Exclusion Criteria:~* Currently receiving any treatment for osteoporosis, including estrogen and estrogenic-like compounds~* Received radiation treatment to any site at any time in the past~* Received chemotherapy for cancer at any time in the past~* Any active cancer~* Surgical repair (or attempted repair) of the fracture site in the pelvis~* Use of any bone-active medications~* Use of anticonvulsant therapy~* Use of immunosuppressants~* Any renal, gastrointestinal, liver, or metabolic bone disease~* Pregnancy~* High calcium, parathyroid hormone, or alkaline phosphatase, as based on laboratory results

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injection (Type: ACTIVE_COMPARATOR): 30 participants will receive teriparatide (Forteo) injection pens.
- Placebo (Type: PLACEBO_COMPARATOR): 30 participants will receive placebo injection pens.

Based on this trial design, predict the completion outcome and termination type (if applicable).